赛妥珠单抗用于治疗中重度斑块状银屑病的研究进展

Research progress of certolizumab pegol in the treatment of moderate to severe patchy psoriasis

赛妥珠单抗( Certolizumab pegol,CZP),商品名Cimzia,是一种聚乙二醇人源化Fab 片段的抗TNF-α单克隆抗体。FDA 于2018 年首次批准CZP 用于治疗克罗恩病,该药陆续于2009 - 2015 年获得FDA 和EMA 的许可用于治疗类风湿性关节炎、活动性银屑病关节炎、强直性脊柱炎和中轴型脊柱炎。FDA 于2018 年再次扩大CZP 的应用范围,批准其用于适合全身治疗或光疗的中重度斑块状银屑病成年患者的治疗,使CZP 成为首个适用于该病的无需融和的聚乙醇化抗TNF 治疗方案的药物。本文对CZP 的作用机制、药动学、药效学、临床评价和安全性等方面进行综述,为临床治疗和深入研究提供参考。

Certolizumab pegol ( CZP),with the brand name of Cimzia, is an anti-TNF-α monoclonal antibody of polyethylene glycol human-derived Fab 'fragment. In 2008 the FDA first approved CZP for the treatment of Crohn's disease. From 2009 to 2015, the drug had already been approved for the cure of rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis and axial spondyloarthritis. CZP was first approved by FDA in 2018 for the treatment of plaque psoriasis which was suitable for systemic or phototherapy treatment,which made CZP become the first polyethylene ethanol anti-TNF-α agent drug without fusion for the treatment of plaque psoriasis. This article reviews the mechanism, pharmacokinetics,pharmacodynamics, clinical evaluation and safety of CZP,which provides a reference for clinical treatment and in-depth research.